Related Experiment Video

Updated: Oct 9, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis

T Hitsumoto1, H Ohsawa, T Uchi

  • 1Department of Clinical Medicine, Cardiovascular Center, Internal Medicine, Sakura Hospital, School of Medicine, TOHO University, Sakura-City, Chiba, Japan.

Atherosclerosis
|February 13, 2001
PubMed

Insights

Low preheparin lipoprotein lipase (LPL) mass, an indicator of enzyme levels before heparin administration, is linked to the progression of coronary atherosclerosis. This finding suggests preheparin LPL mass may be a significant factor in heart disease development.

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Biochemistry

Background:

  • Preheparin serum contains lipoprotein lipase (LPL) mass with minimal activity.
  • The clinical relevance of preheparin serum LPL mass remains largely undetermined.
  • Understanding LPL's role in cardiovascular disease is crucial for risk assessment.

Purpose of the Study:

  • To investigate preheparin LPL mass levels in patients with coronary atherosclerosis.
  • To compare these levels with those in healthy individuals.
  • To assess the correlation between preheparin LPL mass and coronary atherosclerosis severity.

Main Methods:

  • Studied 70 men with coronary artery disease symptoms undergoing coronary angiography (stenosis defined as >= 75%).
  • Included a control group of 77 healthy men.
  • Analyzed preheparin LPL mass in relation to other cardiovascular risk factors.

Main Results:

  • Patients with coronary atherosclerosis exhibited lower preheparin LPL mass compared to normal coronary and control groups.
  • Multivariate analysis identified preheparin LPL mass as a significant predictor for the number of coronary lesions (t-value = -2.53).

Conclusions:

  • Reduced preheparin LPL mass is associated with coronary atherosclerosis.
  • Low preheparin LPL mass may play a critical role in the advancement of coronary atherosclerosis.
  • Preheparin LPL mass warrants further investigation as a potential biomarker for cardiovascular risk.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...